NEW YORK / Apr 30, 2024 / Business Wire / MultiPlan Corporation (NYSE:MPLN) (“MultiPlan” or the “Company”), a leading provider of technology and data-enabled end-to-end cost management, payment and revenue integrity solutions to the U.S. healthcare industry, today announced that members of its management team will participate in person at the following conferences in May 2024:
It is expected that current trends and first quarter 2024 performance will be discussed.
A live webcast and audio archive of the fireside chat at the Bank of America Healthcare Conference, if available, may be accessed through the investor relations section of MultiPlan’s website at investors.multiplan.us/events-and-presentations. Individuals who listen to the event will be presumed to have read MultiPlan’s recent filings with the Securities and Exchange Commission. Following the presentation, a webcast replay will be available for 30 days.
About MultiPlan
MultiPlan is committed to bending the cost curve in healthcare by delivering transparency, fairness, and affordability to the US healthcare system. Our focus is on identifying medical savings, helping to lower out-of-pocket costs, and reducing or eliminating balance billing for healthcare consumers. Leveraging sophisticated technology, data analytics, and a team rich with industry experience, MultiPlan interprets customers’ needs and customizes innovative solutions that combine its payment and revenue integrity, network-based, data and decision science, and analytics-based services. MultiPlan delivers value to more than 700 healthcare payors, over 100,000 employers, 60 million consumers, and 1.4 million contracted providers. For more information, visit multiplan.com.
Last Trade: | US$29.20 |
Daily Volume: | 0 |
Market Cap: | US$472.160M |
August 06, 2025 July 08, 2025 May 22, 2025 May 08, 2025 |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load